Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$15.22 CAD
Change Today +0.49 / 3.33%
Volume 3.2K
As of 3:59 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

novadaq technologies inc (NDQ) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/15/15 - C$21.50
52 Week Low
10/17/14 - C$11.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

novadaq technologies inc (NDQ) Related Businessweek News

No Related Businessweek News Found

novadaq technologies inc (NDQ) Details

Novadaq Technologies Inc. develops, manufactures, and markets fluorescence imaging products and therapeutic devices for use by surgeons in the operating room and other clinical settings in the United States and internationally. The company’s proprietary imaging platform is used to visualize blood vessels, nerves, and the lymphatic system during surgical procedures. It offers SPY Elite imaging system for use in coronary artery bypass graft surgery, cardiovascular surgery, plastic surgery, reconstructive surgery, microsurgery, organ transplant, and gastrointestinal surgery. The company’s PINPOINT endoscopic fluorescence imaging system is used for traditional endoscope and to obtain fluorescence images on demand or in a simultaneous imaging mode during minimally invasive surgery; and LUNA imaging system enables physicians treating chronic wounds to distinguish perfused and non-perfused tissue during the treatment of diabetic foot ulcers, pressure sores, and other serious chronic non-healing wounds. It also provides DermACELL tissue products for use in breast reconstruction surgeries, as well as in the treatment of diabetic foot ulcers and chronic non-healing wounds. In addition, the company offers Firefly imaging systems for use in robotic surgery; SPY analysis toolkit, a post-processing software that allows physicians to enhance and apply objective analysis tools to SPY Elite and LUNA images; and CO2 heart laser system for transmyocardial revascularization. Novadaq Technologies Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

Founded in 2000

novadaq technologies inc (NDQ) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $390.2K
Co-Founder, Senior Vice President and General...
Total Annual Compensation: $222.7K
Chief Financial Officer
Total Annual Compensation: $206.4K
Vice President of Marketing
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2014.

novadaq technologies inc (NDQ) Key Developments

Novadaq Technologies Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 12:40 PM

Novadaq Technologies Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 12:40 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.

Novadaq Technologies Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 11:20 AM

Novadaq Technologies Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 11:20 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Arun Menawat, Chief Executive Officer, President and Director.

Novadaq Technologies Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms financial Guidance for the Full Year of 2015

Novadaq Technologies Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported a wider-than-expected net loss on higher revenues that still were below analysts' consensus forecasts. The company’s net loss narrowed to $11.3 million or $0.20 per basic and diluted share from a net loss of $16.1 million or $0.29 per basic and diluted share a year earlier, missing the consensus forecasts for a loss of $0.09 per share. The decrease in net loss was a result of non-cash warrant revalution income of $23,000 compared to non-cash revaluation expenses of $11.9 million, and a $0.8 million increase in gross profit. Sales increased 13.6% year-on-year to $11.7 million, yet fell short of expectations of $13.1 million. Total revenues were $11,691,341 compared to $10,298,222 a year ago. Loss from operations was $11,335,716 compared to $4,246,227 a year ago. Loss before income taxes was $11,285,391 compared to $16,096,765 a year ago. Cash used in operating activities was $8,607,603 compared to $3,724,750 a year ago. Purchase of property and equipment was $1,206,099 compared to $2,290,707 a year ago. For the full-year, the company reaffirmed its sales outlook of $65 million, representing total year-over-year revenue growth of approximately 40%. The company reported normal gross profit about 65%, the company think that it should see slight movement upward from 65%, but it don't think that it will get to 70%. The company thinks it will be mid to high 60%’s for the balance of the year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NDQ:CN C$15.22 CAD +0.49

NDQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CryoLife Inc $11.29 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation NDQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.9x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVADAQ TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at